Insider · CIK 0001737231
Jennifer Zachary
Files at MRK (Merck & Co., Inc.), RGNX (REGENXBIO Inc.). First filing Feb 9, 2026, latest Aug 13, 2026.
In brief
Jennifer Zachary files SEC Form 4 as officer and director at MRK (Merck & Co., Inc.), and also at RGNX (REGENXBIO Inc.). Since Feb 9, 2026, Jennifer Zachary has reported 0 open-market buys worth $0 and 2 open-market sells worth $25M, the latest filed on Aug 13, 2026.
A track record needs three past buys with six months of prices behind them; Jennifer Zachary has 0, so none is measured yet.
The newest scored trade: sold $11M of MRK on Aug 12, 2026, filed Aug 13, 2026, scored 60 (notable). In the last 12 months: 0 buys worth $0 and 2 sells worth $25M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
MRK: Merck & Co., Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 60Notable | Merck & Co., Inc. | $11M 80,315 shares | -64% | +75% from low0% from high | |
| 60Notable | Merck & Co., Inc. | $14M 121,573 shares | -128% | +65% from low-4% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 12, 2026 | MRK MERCK & CO., INC. | 80,315 0.00% of outstanding | $11M | Aug 12, 2026 | none |
| Feb 9, 2026 | MRK MERCK & CO., INC. | 121,573 0.00% of outstanding | $14M | Feb 9, 2026 | none |
Transactions
Every row this insider has filed, 26 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | MRK Merck & Co., Inc. | MOption exercise Common Stock | +41,494 | $117.89 | $4.9M | 112,391 | Aug 13, 2026 |
| Aug 12, 2026 | MRK Merck & Co., Inc. | MOption exercise Common Stock | +13,433 | $84.71 | $1.1M | 125,824 | Aug 13, 2026 |
| Aug 12, 2026 | MRK Merck & Co., Inc. | SOpen-market sale Common Stock | -80,315 | $133.46 | $11M | 45,509 | Aug 13, 2026 |
| Aug 12, 2026 | MRK Merck & Co., Inc. | MOption exercise Stock Option (Right to Buy)derivative | -41,494 | $0.00 | $0 | 0 | Aug 13, 2026 |
| Aug 12, 2026 | MRK Merck & Co., Inc. | MOption exercise Stock Option (Right to Buy)derivative | -13,433 | $0.00 | $0 | 0 | Aug 13, 2026 |
| May 29, 2026 | RGNX REGENXBIO Inc. | AGrant or award Common Stock | +9,807 | $0.00 | $0 | 31,871 | Jun 2, 2026 |
| May 29, 2026 | RGNX REGENXBIO Inc. | AGrant or award Stock Options (Right to Buy)derivative | +46,600 | $0.00 | $0 | 46,600 | Jun 2, 2026 |
| May 5, 2026 | MRK Merck & Co., Inc. | AGrant or award Restricted Stock Unitderivative | +12,064 | $0.00 | $0 | 12,064 | May 7, 2026 |
| May 5, 2026 | MRK Merck & Co., Inc. | AGrant or award Stock Option (Right to Buy)derivative | +35,312 | $0.00 | $0 | 35,312 | May 7, 2026 |
| Apr 29, 2026 | MRK Merck & Co., Inc. | MOption exercise Common Stock | +2,951 | $110.03 | $325k | 72,351 | May 1, 2026 |
| Apr 29, 2026 | MRK Merck & Co., Inc. | FTax withholding Common Stock | -1,454 | $110.03 | $160k | 70,897 | May 1, 2026 |
| Apr 29, 2026 | MRK Merck & Co., Inc. | MOption exercise Restricted Stock Unitderivative | -2,951 | $0.00 | $0 | 5,903 | May 1, 2026 |
| Feb 9, 2026 | MRK Merck & Co., Inc. | MOption exercise Common Stock | +25,946 | $119.15 | $3.1M | 94,862 | Feb 9, 2026 |
| Feb 9, 2026 | MRK Merck & Co., Inc. | SOpen-market sale Common Stock | -25,946 | $119.15 | $3.1M | 68,916 | Feb 9, 2026 |
| Feb 9, 2026 | MRK Merck & Co., Inc. | MOption exercise Common Stock | +56,792 | $119.15 | $6.8M | 125,708 | Feb 9, 2026 |
| Feb 9, 2026 | MRK Merck & Co., Inc. | SOpen-market sale Common Stock | -56,792 | $119.15 | $6.8M | 68,916 | Feb 9, 2026 |
| Feb 9, 2026 | MRK Merck & Co., Inc. | MOption exercise Common Stock | +38,835 | $119.15 | $4.6M | 107,751 | Feb 9, 2026 |
| Feb 9, 2026 | MRK Merck & Co., Inc. | SOpen-market sale Common Stock | -38,835 | $119.15 | $4.6M | 68,916 | Feb 9, 2026 |
| Feb 9, 2026 | MRK Merck & Co., Inc. | MOption exercise Stock Option (Right to Buy)derivative | -25,946 | $0.00 | $0 | 0 | Feb 9, 2026 |
| Feb 9, 2026 | MRK Merck & Co., Inc. | MOption exercise Stock Option (Right to Buy)derivative | -56,792 | $0.00 | $0 | 0 | Feb 9, 2026 |
| Feb 9, 2026 | MRK Merck & Co., Inc. | MOption exercise Stock Option (Right to Buy)derivative | -38,835 | $0.00 | $0 | 0 | Feb 9, 2026 |
| Jan 26, 2026 | MRK Merck & Co., Inc. | AGrant or award Common Stock | +11,583 | $107.40 | $1.2M | 68,916 | Jan 28, 2026 |
| May 30, 2025 | RGNX REGENXBIO Inc. | AGrant or award Common Stock | +7,768 | $0.00 | $0 | 22,064 | Jun 3, 2025 |
| May 30, 2025 | RGNX REGENXBIO Inc. | AGrant or award Stock Options (Right to Buy)derivative | +39,815 | $0.00 | $0 | 39,815 | Jun 3, 2025 |
| Apr 29, 2025 | MRK Merck & Co., Inc. | AGrant or award Restricted Stock Unitderivative | +8,854 | $0.00 | $0 | 8,854 | May 1, 2025 |
| Apr 29, 2025 | MRK Merck & Co., Inc. | AGrant or award Stock Option (Right to Buy)derivative | +40,301 | $0.00 | $0 | 40,301 | May 1, 2025 |
Questions about Jennifer Zachary
Answered from the filings on this page, as of the latest one.
Is Jennifer Zachary buying or selling?
In the last 12 months Jennifer Zachary reported 0 open-market buys worth $0 and 2 open-market sells worth $25M on SEC Form 4; the latest was sold $11M of MRK on Aug 12, 2026. Grants, option exercises and tax withholding are not counted.
How did Jennifer Zachary's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jennifer Zachary has 0.
Where does Jennifer Zachary file Form 4?
Jennifer Zachary has filed Form 4 at MRK (Merck & Co., Inc.) as EVP, General Counsel; RGNX (REGENXBIO Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.